Overview

Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations

Status:
Completed

Trial end date:
2012-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is: - to evaluate the safety of oral QLT091001 - to evaluate whether 7-day treatment with oral QLT091001 can improve visual function in subjects with LCA or RP due to RPE65 or LRAT mutations - to evaluate duration of visual function improvement (if observed)

Phase:

Phase 1

Details

Lead Sponsor:

QLT Inc.

Treatments:

Retinol acetate
Vitamin A